Literature DB >> 9130398

Application of stable isotope tracer combined with mass spectrometric detection for studying myo-inositol uptake by cultured neurons from fetal mouse: effect of trisomy 16.

L D Acevedo1, H W Holloway, S I Rapoport, H U Shetty.   

Abstract

A gas chromatographic (GC)/mass spectrometric method for studying myo-inositol uptake by neurons in vitro is described. Cultured cortical neurons from fetuses of diploid and trisomy 16 mouse (animal model for Down syndrome) were incubated with a physiological concentration of hexadeuterated myo-inositol for 2-40 min. Washed cells were lysed and scyllo-inositol (internal standard) was added to the intracellular material which contained labeled myo-inositol taken up by the cells as well as the endogenous, unlabeled myo-inositol. The samples were evaporated to dryness and the analytes were converted into acetate derivatives. The components were separated by capillary GC, and the m/z 379 ion for labeled myo-inositol and the m/z 373 ion for myo-inositol and scyllo-inositol generated by chemical ionization in an ion trap mass spectrometer were monitored. Quantitation of the deuterium-labeled myo-inositol taken up by the neuron along with endogenous myo-inositol was achieved for 2-40 min of incubation. The labeled myo-inositol uptake was linear for up to 20 min and was Na+ dependent in these neurons. This non-radioisotope method was used to demonstrate a significant (40%) increase in the rate of myo-inositol uptake by cortical neurons from the trisomy 16 mouse relative to control neurons. An increased myo-inositol uptake is consistent with evidence that the myo-inositol transporter gene is on both human chromosome 21 and mouse chromosome 16, and that myo-inositol concentrations are elevated in cerebrospinal fluid from adult Down syndrome individuals and brains from the fetal trisomy 16 mouse.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9130398     DOI: 10.1002/(SICI)1096-9888(199704)32:4<395::AID-JMS487>3.0.CO;2-#

Source DB:  PubMed          Journal:  J Mass Spectrom        ISSN: 1076-5174            Impact factor:   1.982


  7 in total

1.  Measuring brain uptake and incorporation into brain phosphatidylinositol of plasma myo-[2H6]inositol in unanesthetized rats: an approach to estimate in vivo brain phosphatidylinositol turnover.

Authors:  Kaizong Ma; Joseph Deutsch; Nelly E Villacreses; Thad A Rosenberger; Stanley I Rapoport; H Umesha Shetty
Journal:  Neurochem Res       Date:  2006-06-22       Impact factor: 3.996

2.  Ts65Dn mouse, a Down syndrome model, exhibits elevated myo-inositol in selected brain regions and peripheral tissues.

Authors:  H U Shetty; R J Siarey; Z Galdzicki; J Stoll; S I Rapoport
Journal:  Neurochem Res       Date:  2000-04       Impact factor: 3.996

3.  Inositol synthesis regulates the activation of GSK-3α in neuronal cells.

Authors:  Cunqi Ye; Miriam L Greenberg
Journal:  J Neurochem       Date:  2014-11-17       Impact factor: 5.372

4.  Knockdown of Myo-Inositol Transporter SMIT1 Normalizes Cholinergic and Glutamatergic Function in an Immortalized Cell Line Established from the Cerebral Cortex of a Trisomy 16 Fetal Mouse, an Animal Model of Human Trisomy 21 (Down Syndrome).

Authors:  Ana María Cárdenas; Paola Fernández-Olivares; Ignacio Díaz-Franulic; Arlek M González-Jamett; Takeshi Shimahara; Juan Segura-Aguilar; Raúl Caviedes; Pablo Caviedes
Journal:  Neurotox Res       Date:  2017-07-10       Impact factor: 3.911

5.  Identification of myo-inositol-3-phosphate synthase isoforms: characterization, expression, and putative role of a 16-kDa gamma(c) isoform.

Authors:  Ratnam S Seelan; Jaganathan Lakshmanan; Manuel F Casanova; Ranga N Parthasarathy
Journal:  J Biol Chem       Date:  2009-02-02       Impact factor: 5.157

Review 6.  Myo-Inositol and Its Derivatives: Their Emerging Role in the Treatment of Human Diseases.

Authors:  Dhani Raj Chhetri
Journal:  Front Pharmacol       Date:  2019-10-11       Impact factor: 5.810

7.  Neurometabolite mapping highlights elevated myo-inositol profiles within the developing brain in down syndrome.

Authors:  Prachi A Patkee; Ana A Baburamani; Katherine R Long; Ralica Dimitrova; Judit Ciarrusta; Joanna Allsop; Emer Hughes; Johanna Kangas; Grainne M McAlonan; Mary A Rutherford; Enrico De Vita
Journal:  Neurobiol Dis       Date:  2021-03-09       Impact factor: 5.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.